- Home
- ORIC vs IVA Comparison
ORIC vs IVA Comparison
Compare ORIC & IVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ORIC
- IVA
- Stock Information
- Founded
- ORIC 2014
- IVA 2011
- Country
- ORIC United States
- IVA France
- Employees
- ORIC N/A
- IVA N/A
- Industry
- ORIC Biotechnology: Pharmaceutical Preparations
- IVA Biotechnology: Pharmaceutical Preparations
- Sector
- ORIC Health Care
- IVA Health Care
- Exchange
- ORIC Nasdaq
- IVA Nasdaq
- Market Cap
- ORIC 362.9M
- IVA 359.6M
- IPO Year
- ORIC 2020
- IVA 2020
- Fundamental
- Price
- ORIC $5.08
- IVA $3.62
- Analyst Decision
- ORIC Strong Buy
- IVA Strong Buy
- Analyst Count
- ORIC 8
- IVA 4
- Target Price
- ORIC $18.83
- IVA $10.50
- AVG Volume (30 Days)
- ORIC 630.2K
- IVA 19.2K
- Earning Date
- ORIC 05-05-2025
- IVA 03-26-2025
- Dividend Yield
- ORIC N/A
- IVA N/A
- EPS Growth
- ORIC N/A
- IVA N/A
- EPS
- ORIC N/A
- IVA N/A
- Revenue
- ORIC N/A
- IVA $14,591,573.00
- Revenue This Year
- ORIC N/A
- IVA $15.38
- Revenue Next Year
- ORIC N/A
- IVA $24.22
- P/E Ratio
- ORIC N/A
- IVA N/A
- Revenue Growth
- ORIC N/A
- IVA N/A
- 52 Week Low
- ORIC $3.90
- IVA $1.53
- 52 Week High
- ORIC $14.67
- IVA $4.05
- Technical
- Relative Strength Index (RSI)
- ORIC 44.71
- IVA 56.12
- Support Level
- ORIC $4.52
- IVA $3.40
- Resistance Level
- ORIC $5.83
- IVA $3.77
- Average True Range (ATR)
- ORIC 0.52
- IVA 0.25
- MACD
- ORIC 0.07
- IVA -0.04
- Stochastic Oscillator
- ORIC 40.58
- IVA 43.79
About ORIC Oric Pharmaceuticals Inc.
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.
About IVA Inventiva S.A. American Depository Shares
Inventiva SA is a France-based biopharmaceutical company specialized in developing drugs that impact on nuclear receptors, transcription factors and epigenetic modulation. The company is focused on developing its product candidate, lanifibranor, for the treatment of patients with non-alcoholic steatohepatitis, or NASH, a disease for which there are currently no approved therapies. The company is also involved in developing a portfolio of pre-clinical therapy programs. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis, and rare diseases. All the company's operations are in France. Majority of the group's revenue is derived from its research partnerships with AbbVie and BI.